Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07808359) titled 'Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma' on Sept. 2.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Latin American Cooperative Oncology Group
Condition:
Penile Squamous Cell Carcinoma
Metastatic Penile Squamous Cell Carcinoma
Intervention:
Drug: Amivantamab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 2026
Target Sample Size: 58
Countries of Recruitment:
Brazil
To know more, visit https:...